
    
      The trial was designed as a multicentre randomised open-label trial with blinded data
      management and data analyses, to assess whether either treatment was superior to the other.
      The trial was performed on behalf of the Italian Society for the study of Thalassemia and
      Haemoglobinopathies (SoSTE). The investigators initiated, carried out, and controlled the
      trial, which was conducted without influence of the non-commercial sponsor.16
    
  